Tiva to sell generic Viagra in 2017

Bloomberg NewsDecember 17, 2013 

— Generic Viagra will hit the market more than two years earlier than expected under a settlement reached by Teva Pharmaceutical Industries and the maker of the impotence drug, Pfizer.

Teva can enter the market on Dec. 11, 2017, and will pay patent royalties through the expiration of the Viagra patent in April 2020, New York-based Pfizer said in a statement. Other terms weren’t disclosed.

Viagra, whose chemical name is sildenafil citrate, is one of Pfizer’s best-known medicines. The drug sold $2.05 billion in 2012, its best year ever. Pfizer earlier this year began selling the blue pill through a company-sponsored website to combat counterfeit versions sold online.

The medicine came from a group of compounds considered during research to treat high blood pressure and angina. The assistance with erectile dysfunction was a side effect discovered during testing, and the patent, issued in 2002, is for use of the compound to treat impotence.

Some aspects of the patent were earlier rejected in 2010 because it was similar to a Chinese herb known as Horny Goat Weed. Teva lost its bid to invalidate the rest of the patent at trial, and was appealing the case. The U.S. Court of Appeals for the Federal Circuit on Tuesday dismissed the appeals.

Teva, based in Petach Tikva, Israel, spiked briefly on the news. Shares were down 9 cents, to $39.63 at 12:36 p.m., after earlier trading as high as $40.10.

News & Observer is pleased to provide this opportunity to share information, experiences and observations about what's in the news. Some of the comments may be reprinted elsewhere in the site or in the newspaper. We encourage lively, open debate on the issues of the day, and ask that you refrain from profanity, hate speech, personal comments and remarks that are off point. Thank you for taking the time to offer your thoughts.

Commenting FAQs | Terms of Service